
{"id":6,"date":"2012-03-21T17:10:18","date_gmt":"2012-03-21T17:10:18","guid":{"rendered":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/?page_id=6"},"modified":"2026-04-03T18:47:32","modified_gmt":"2026-04-03T18:47:32","slug":"home","status":"publish","type":"page","link":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/","title":{"rendered":"GRDZELISHVILI LAB                                                     Molecular Virology and Oncolytic Virotherapy for Pancreatic Cancer"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Valery Z. Grdzelishvili, Ph.D.<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><em><strong>Professor, Molecular Virology and Cancer Therapy<\/strong><\/em><\/h3>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-full is-resized\"><a href=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/09\/Valery-Photo-3.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"591\" height=\"591\" src=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/09\/Valery-Photo-3.jpg\" alt=\"\" class=\"wp-image-927\" style=\"width:404px;height:auto\" srcset=\"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/09\/Valery-Photo-3.jpg 591w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/09\/Valery-Photo-3-300x300.jpg 300w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/09\/Valery-Photo-3-150x150.jpg 150w\" sizes=\"auto, (max-width: 591px) 100vw, 591px\" \/><\/a><\/figure>\n<\/div>\n\n\n<h5 class=\"wp-block-heading\"><strong>Dr. Grdzelishvili\u2019s laboratory focuses on the molecular biology of nonsegmented negative-strand (NNS) RNA viruses (order <em>Mononegavirales<\/em>). This group includes several significant human and animal pathogens, such as rabies, measles, mumps, Ebola, Marburg, Nipah, and Hendra viruses. The laboratory is particularly interested engineering NNS RNA viruses, primarily vesicular stomatitis virus (VSV), as replication-competent oncolytic agents for cancer therapy. A major area of research involves identifying viral and cellular factors that influence the susceptibility or resistance of pancreatic cancer cells to VSV and other oncolytic viruses, as well as developing innovative strategies to overcome resistance to oncolytic virotherapy in pancreatic cancer.<\/strong><\/h5>\n\n\n\n<p><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=grdzelishvili+v&amp;sort=date\">Publications at PubMed<\/a><\/strong>&nbsp;\/ <strong><a href=\"https:\/\/scholar.google.com\/citations?hl=en&amp;user=md3R3DEAAAAJ&amp;view_op=list_works&amp;sortby=pubdate\">Dr. Grdzelishvili&#8217;s Google Scholar Profile<\/a><\/strong> \/ <a href=\"https:\/\/x.com\/Virology_Lab\" data-type=\"link\" data-id=\"https:\/\/x.com\/Virology_Lab\"><strong>Grdzelishvili Lab Twitter<\/strong><\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p><em><strong>Keywords: <\/strong>molecular virology, cancer biology, anticancer therapy based on replication-competent viruses (&#8220;oncolytic virotherapy&#8221;), virus-host interactions in normal and cancer cells, host factors of virus replication in normal and cancer cells, innate immunity in normal and cancer cells, virus-based gene therapy, vaccine vectors, negative-strand RNA viruses (order Mononegavirales)<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"610\" src=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226-1024x610.jpg\" alt=\"\" class=\"wp-image-964\" srcset=\"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226-1024x610.jpg 1024w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226-300x179.jpg 300w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226-768x458.jpg 768w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226-1536x916.jpg 1536w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2026\/04\/Lab-Photo-040226.jpg 1783w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><em>Left to Right (click to expand): <\/em><strong>Valery Grdzelishvili, Timo Taffe, Matthew Widrick, Cassandra (Cassie) Catacalos, <strong>Nathaniel Foret, Emanuel Helleryd, <\/strong>David Janumyan, <\/strong>, <strong>Kyra Price<\/strong>, <strong>Jacob Hawkins, Charlotte Johnstone<\/strong><\/p>\n\n\n\n<p><em>Second Row: <\/em><strong>Sophie the Sheltie<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud.png\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud.png\" alt=\"\" class=\"wp-image-879\" style=\"width:618px;height:auto\" srcset=\"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud.png 1024w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud-300x300.png 300w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud-150x150.png 150w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2025\/07\/lab-word-cloud-768x768.png 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n<h3><strong>Valery Z. Grdzelishvili, Ph.D. \/ Short Bio<\/strong><\/h3>\n<hr data-start=\"1070\" data-end=\"1073\" \/>\n<p><strong>Academic Degrees<\/strong><\/p>\n<ul>\n<li>Ph.D. in Virology:\u00a0<a href=\"http:\/\/www.msu.ru\/en\/tour\/\"><em><strong>Lomonosov<\/strong><\/em><strong> Moscow State University<\/strong><\/a>, Department of Virology, Russia (1998)<\/li>\n<li>M.S.\/B.S. in Biochemistry: <em><strong><a href=\"http:\/\/www.msu.ru\/en\/tour\/\" target=\"_blank\" rel=\"noopener noreferrer\">L<\/a><a href=\"http:\/\/www.msu.ru\/en\/tour\/\">omonosov<\/a><\/strong><\/em><a href=\"http:\/\/www.msu.ru\/en\/tour\/\"><strong> Moscow State University<\/strong><\/a>, Department of Virology, Russia (1995)<\/li>\n<\/ul>\n<h4><strong>Professional Experience<\/strong><\/h4>\n<ul>\n<li>Professor (July 2018-present): <strong><a href=\"http:\/\/biology.uncc.edu\/\">University of North Carolina at Charlotte, Department of Biological Sciences<\/a><\/strong><\/li>\n<li>Associate Professor (July 2012-June 2018): <strong><a href=\"http:\/\/biology.uncc.edu\/\">University of North Carolina at Charlotte, Department of Biological Sciences<\/a><\/strong><\/li>\n<li>Assistant Professor (July 2006-June2012): <strong><a href=\"http:\/\/biology.uncc.edu\/\">University of North Carolina at Charlotte, Department of Biological Sciences<\/a><\/strong><\/li>\n<li>Research Assistant Professor (2004-2006): <strong><a href=\"http:\/\/www.mgm.ufl.edu\/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Florida College of Medicine, Dept. of Molecular Genetics and Microbiology<\/a><\/strong>\u00a0<em>[Mentor: Dr. Sue Moyer]<\/em><\/li>\n<li>Postdoctoral Research Associate (2001 &#8211; 2004): <strong><a href=\"http:\/\/virology.wisc.edu\/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Wisconsin-Madison, Institute for Molecular Virology<\/a>\u00a0and<\/strong><span style=\"color: #3366ff\">\u00a0<strong><a href=\"https:\/\/www.hhmi.org\">Howard Hughes Medical\u00a0Institute (HHMI)<\/a><\/strong><\/span><strong>\u00a0<\/strong><em>[Mentor: Dr. Paul Ahlquist]<\/em><\/li>\n<li>Postdoctoral Research Associate (1999 &#8211; 2000):\u00a0University of Florida,\u00a0<strong><a href=\"http:\/\/ifas.ufl.edu\">Institute of Food and Agricultural Sciences, CREC<\/a><\/strong> [<em>Mentor: Dr. William Dawson]<\/em><\/li>\n<\/ul>\n<h4><strong>Selected Peer-Reviewed Publications (see all publications in the &#8220;Lab Publications&#8221; tab)<\/strong><\/h4>\n<ol>\n<li>Catacalos-Goad C., Goad D.W., Holbrook M.C., Krueger Q., Wilson I.M., Hajjar M.A., <strong>Grdzelishvili V.Z..<\/strong> 2025 <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2950329925001584\">&#8220;Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus&#8221;<\/a>, <em><strong>Molecular Therapy Oncology<\/strong><\/em>, Volume 33, Issue 4, 201089, https:\/\/doi.org\/10.1016\/j.omton.2025.201089.<\/li>\n<li>Catacalos-Goad C, Johnstone C, <strong>Grdzelishvili VZ. <\/strong>2025 <a href=\"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/627\">&#8220;Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends&#8221;<\/a> <em><strong>Current Oncology.<\/strong><\/em> 2025 Nov 7;32(11):627. doi: 10.3390\/curroncol32110627. [PMID: 41294689].<\/li>\n<li>\n<div class=\"citation-text\">Catacalos-Goad C, Hawkins J, Krueger Q, Foret N, <strong>Grdzelishvili VZ.<\/strong> 2025 <a href=\"https:\/\/journals.asm.org\/doi\/full\/10.1128\/jvi.02284-24?rfr_dat=cr_pub++0pubmed&amp;url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org\">&#8220;METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state&#8221;<\/a> <b><i>Journal of Virology<\/i><\/b> 2025 May 20;99(5):e0228424. doi: 10.1128\/jvi.02284-24. Epub 2025 Apr 11. [PMID: 40214229]<\/div>\n<\/li>\n<li>\n<div class=\"citation-text\">Goad DW, Nesmelova AY, Yohe LR, <strong>Grdzelishvili VZ.<\/strong> 2023 <a href=\"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.01005-23\">&#8220;Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells&#8221;<\/a> <b><i>Journal of Virology<\/i><\/b> 2023 Sep 6:e0100523. doi: 10.1128\/jvi.01005-23. [PMID: 37671865]<\/div>\n<\/li>\n<li>Goad D.W., Bressy C., Holbrook M.C.,\u00a0and\u00a0<strong>Grdzelishvili VZ.\u00a0<\/strong>2022 <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2372770521001686?via%3Dihub\">\u201cAcquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus\u201d<\/a>\u00a0<em><strong><span class=\"jrnl\" title=\"Molecular therapy oncolytics\">Molecular Therapy Oncolytics<\/span><\/strong><\/em>. 2022 24:59-76. [PMID: 34977342]<\/li>\n<li>Seegers S.L., Frasier C., Greene S., Nesmelova I.V., and\u00a0<strong>Grdzelishvili VZ.<\/strong>\u00a02019\u00a0<a href=\"https:\/\/jvi.asm.org\/content\/94\/3\/e01643-19.long\">\u201cExperimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses With Improved Replication in Virus-Resistant Pancreatic Cancer Cells\u201d<\/a>.\u00a0<b><i>Journal of Virology,<\/i><\/b> 2020 Jan 17;94(3):e01643-19. [PMID: 31694943]<\/li>\n<li>Bressy C, Droby GN, Maldonado BD, Steuerwald N, and\u00a0<strong>Grdzelishvili VZ.<\/strong>\u00a02019\u00a0<a href=\"https:\/\/jvi.asm.org\/content\/93\/4\/e01885-18\">\u201cCell Cycle Arrest in G(2)\/M Phase Enhances Replication of Interferon-Sensitive Cytoplasmic RNA Viruses via Inhibition of Antiviral Gene Expression\u201d<\/a>.\u00a0<b><i>Journal of Virology,<\/i><\/b> 2019 Feb 5;93(4). pii: e01885-18. [PMID: 30487274]<\/li>\n<li>Felt S.A., Droby G.N.,\u00a0<strong>Grdzelishvili V.Z.\u00a0<\/strong>2017\u00a0<a href=\"http:\/\/jvi.asm.org\/content\/91\/16\/e00461-17.full?sid=db4f52e6-51c0-4804-9af4-c6db4b899c50\">\u201cRuxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus\u201d<\/a>\u00a0<b><i>Journal of Virology<\/i><\/b>, 2017, 91(16)<\/li>\n<li>Hastie E., Cataldi M., Moerdyk-Schauwecker M.J., Felt S.A., Steuerwald N., <strong>Grdzelishvili V.Z.<\/strong>\u00a02016 <a href=\"https:\/\/www.oncotarget.com\/article\/11202\/text\/\">\u201cNovel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus\u201d\u00a0<\/a><em><strong>Oncotarget.<\/strong><\/em> 2016 [PMID:\u00a0<span class=\"docsum-pmid\">27533247]<\/span><\/li>\n<li>Cataldi M., Shah N.R., Felt S.A.,\u00a0<strong>Grdzelishvili V.Z.<\/strong>\u00a02015 \u201c<a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0042682215003438\">Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1<\/a>\u201d.\u00a0<strong><em>Virology.<\/em><\/strong>\u00a02015 485:340-354. [PMID: 26331681]<\/li>\n<li>Hastie E., Cataldi M., Steuerwald N., and *<strong>Grdzelishvili V.Z.<\/strong>\u00a02015 \u201c<a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0042682215002287\">An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells<\/a>\u201d\u00a0<strong><em>Virology<\/em><\/strong>. 483:126-140. [PMID: 25965802]<\/li>\n<li>Felt S.A., Moerdyk-Schauwecker M., and\u00a0<b>Grdzelishvili V.Z.\u00a0<\/b>\u00a02015 <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0042682214004838?via%3Dihub\">\u201cInduction of apoptosis in pancreatic cancer cells by\u00a0vesicular stomatitis virus\u201c<\/a>,\u00a0<b><i>Virology<\/i><\/b>, 474:163-173 [PMID:25463614]<\/li>\n<li>Moerdyk-Schauwecker M., Shah N.R. Murphy A.M., Hastie, E., Mukherjee, P., and <b>Grdzelishvili V.Z.\u00a0<\/b>\u00a02013 <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0042682212005740?via%3Dihub\">\u201cResistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling\u201d<\/a>,\u00a0<b><i>Virology<\/i><\/b>, 436:221-34 [PMID:23246628]<\/li>\n<li>Murphy A. M., Besmer D. M., Moerdyk-Schauwecker M., Moestl N., Ornelles D., Mukherjee P., and <b>Grdzelishvili V. Z.<\/b>\u00a0 2012 <a href=\"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.05640-11?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub++0pubmed\">\u201cVesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma&#8221;<\/a>\u00a0<b><i>Journal of Virology<\/i><\/b>, 86:3073-87. [PMID: 22238308]<\/li>\n<\/ol>\n<div id=\"post-6\" class=\"post-6 page type-page status-publish hentry\">\u00a0<\/div>\n<p><span style=\"text-decoration: underline;color: #000000\"><strong>ONCOLYTIC VIROTHERAPY OVERVIEW <\/strong><\/span><\/p>\n<p><span style=\"color: #000000\"><em>(the illustration was created by Dr. Eric Hastie and is from\u00a0<a href=\"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.046672-0\">Hastie and Grdzelishvili\u00a02012 \u201cVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer\u201d Journal of General Virology, 93:2529-45<\/a>)\u00a0<\/em><\/span><\/p>\n<p><span style=\"text-decoration: underline\"><a href=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2012\/03\/Oncolytic-Therpay-Poster.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-206\" src=\"https:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2012\/03\/Oncolytic-Therpay-Poster.jpg\" alt=\"Microsoft Word - 17333195-file00.docx\" width=\"588\" height=\"854\" srcset=\"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2012\/03\/Oncolytic-Therpay-Poster.jpg 795w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2012\/03\/Oncolytic-Therpay-Poster-206x300.jpg 206w, http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-content\/uploads\/sites\/60\/2012\/03\/Oncolytic-Therpay-Poster-705x1024.jpg 705w\" sizes=\"auto, (max-width: 588px) 100vw, 588px\" \/><\/a><\/span><\/p>\n<h5><span style=\"color: #000000\"><strong>Scheme of VSV-based OV therapy.<\/strong> (a) Reverse genetics allows the generation of a recombinant VSV encoding a foreign gene of interest between the VSV G and L genes. The asterisk above M indicates M protein mutation(s) resulting in VSV attenuation in normal cells. Plasmids encoding VSV replication machinery and the modified genome are co-transfected into a cell line, and complete virions are produced and amplified using good manufacturing practices. (b) For evaluation of oncolytic efficacy, VSV can be administered directly, via cell-based delivery, or in combination with other treatments (chemotherapy, radiotherapy, or other OVs). (c) In infected cells, VSV recombinants may express a foreign gene that facilitates the killing of the adjacent uninfected cancer cells (e.g. suicide-gene approach or immunostimulation). Innate antiviral responses and other mechanisms prevent cell death in normal cells. Ideally, stimulation of innate and adaptive immune cells by VSV and\/or the foreign gene product should lead to tumor-specific immune responses, including memory responses that prevent cancer recurrence.<\/span><\/h5>\n<hr \/>","protected":false},"excerpt":{"rendered":"<p>Valery Z. Grdzelishvili, Ph.D. Professor, Molecular Virology and Cancer Therapy Dr. Grdzelishvili\u2019s laboratory focuses on the molecular biology of nonsegmented negative-strand (NNS) RNA viruses (order Mononegavirales). This group includes several significant human and animal pathogens, such as rabies, measles, mumps, Ebola, Marburg, Nipah, and Hendra viruses. The laboratory is particularly interested engineering NNS RNA viruses, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-6","page","type-page","status-publish","hentry"],"jetpack_shortlink":"https:\/\/wp.me\/P2j6yj-6","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/pages\/6","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/comments?post=6"}],"version-history":[{"count":220,"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/pages\/6\/revisions"}],"predecessor-version":[{"id":968,"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/pages\/6\/revisions\/968"}],"wp:attachment":[{"href":"http:\/\/pages.charlotte.edu\/valery-grdzelishvili\/wp-json\/wp\/v2\/media?parent=6"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}